The healthcare costs of heart failure during the last five years of life:A retrospective cohort study by Hollingworth, William et al.
                          Hollingworth, W., Biswas, M., Maishman, R., Purdy, S., Reeves, B., Rogers,
C., & Pufulete, M. (2016). The healthcare costs of heart failure during the
last five years of life: A retrospective cohort study. International Journal of
Cardiology, 224, 132-138. https://doi.org/10.1016/j.ijcard.2016.09.021
Peer reviewed version
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1016/j.ijcard.2016.09.021
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Elsevier at http://www.sciencedirect.com/science/article/pii/S0167527316322148. Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
1 
 
The healthcare costs of heart failure during the last 
five years of life: A retrospective cohort study 
 
William Hollingworth1; Mousumi Biswas1; Rachel L Maishman2; Mark J Dayer3; 
Theresa McDonagh5; Sarah Purdy1; Barnaby C Reeves2; Chris A Rogers2; 
Rachael Williams4; Maria Pufulete2 
 
Affiliations: 
1 School of Social and Community Medicine, University of Bristol, Bristol, UK 
2 Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK 
3 Department of Cardiology, Taunton and Somerset NHS Foundation Trust, Taunton, UK 
4 Clinical Practice Research Datalink, Medicines and Healthcare products Regulatory Agency, 
London, UK 
5 King’s College Hospital, London, UK 
All authors take responsibility for all aspects of the reliability and freedom from bias of the data 
presented and their discussed interpretation. 
 
Corresponding author: 
Professor William Hollingworth 
School of Social and Community Medicine,  
University of Bristol, Bristol, UK 
Tel: +44 117 9287355 
Fax: +44 117 9287325 
Email: William.hollingworth@bristol.ac.uk 
 
Acknowledgement of grant support: 
This study is funded by the National Institute for Health Research (HTA 11/102/03). WH's time on 
the project is partly supported by the National Institute for Health Research (NIHR) Collaboration for 
Leadership in Applied Health Research and Care West (CLAHRC West) at University Hospitals Bristol 
NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the 
NHS, the NIHR or the Department of Health.   
Conflicts of interest: 
RW is an employee of CPRD, who received funding from the University of Bristol to provide access to 
the data for this study. CPRD provide research services for, and receive associated funding from, a 
range of pharmaceutical, academic, governmental, NGO and regulatory organisations. MJD has 
accepted fees for advisory boards from St Jude who make a range of cardiology devices and also 
from Bayer for support for attending conferences.  All other authors declare no conflicts of interest. 
Keywords:  Health Care Costs; HF; Terminal Care; Hospital Costs;  
2 
 
 
Abstract: 
Background 
Evidence on the economic impact of heart failure (HF) is vital in order to predict the cost-
effectiveness of novel interventions. We estimate the health system costs of HF during the last five 
years of life.  
Methods 
We used linked primary care and mortality data accessed through the Clinical Practice Research 
Datalink (CPRD) to identify 1,555 adults in England who died with HF in 2012/13. We used CPRD and 
linked Hospital Episode Statistics to estimate the cost of medications, primary and hospital 
healthcare. Using GLS regression we estimated the relationship between costs, HF diagnosis, 
proximity to death and patient characteristics.   
Results 
In the last 3 months of life, healthcare costs were £8,827 (95% CI £8,357 to £9,296) per patient, 
more than 90% of which were for inpatient or critical care.  In the last 3 months, patients spent on 
average 17.8 (95% CI 16.8 to 18.8) days in hospital and had 8.8 (95% CI 8.4 to 9.1) primary care 
consultations. Most (931/1555; 59.9%) patients were in hospital on the day of death. Mean 
quarterly healthcare costs in quarters after HF diagnosis were higher (£1,439; [95% CI £1,260 to 
£1,619]) than in quarters preceding diagnosis.  Older patients and patients with lower comorbidity 
scores had lower costs. 
Conclusions 
Healthcare costs increase sharply at the end of life and are dominated by hospital care. There is 
potential to save money by implementation and evaluation of interventions that are known to 
reduce hospitalisations for HF, particularly at the end of life.   
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Introduction:  
Global estimates indicate that heart failure (HF) results in $65 billion direct care costs and $43 billion 
in lost productivity annually due to morbidity and premature mortality (1).  In the UK approximately 
500,000 people live with HF (2); this figure is likely to rise as the population continues to age. Each 
year HF is the primary diagnosis in over 150,000 hospital episodes in the UK (2); many of these are 
emergency admissions.  
Median survival following the first hospitalisation with HF has consistently improved in recent years 
(3). However prognosis remains poor; five year mortality was 45.5% among patients with an 
unscheduled hospital admission for HF in England and Wales in 2009(4). Rapid developments in the 
monitoring and treatment of HF have provided clinicians with many more options in selecting 
physical, pharmacological (5) and interventional therapies (6). Evidence-based guidelines (7) aim to 
help clinicians and patients choose the most effective and cost-effective therapies.  The case for 
many novel interventions is based on the presumption that the upfront costs of more intensive 
therapy will be justified in the longer term by improved patient outcomes and savings due to 
reduced hospitalisations.  Therefore, detailed information on the long-term economic impact of HF 
is vital in order to accurately predict the true value of therapy. 
As part of a wider review (8) of the cost-effectiveness of serum B-type natriuretic peptide 
monitoring in patients with HF, we aimed to estimate the cost to the health system of treating 
patients with HF during the last years of life.  Specifically, our objectives were to identify the relative 
contribution of different types of care (i.e. inpatient, outpatient, primary care, and medications) to 
the overall cost and to determine how cost differs by age (<75 years versus ≥75), proximity to death 
and underlying cause of death (circulatory versus other). 
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Methods: 
Cohort identification 
We retrospectively identified a cohort of patients who died of or with HF from the Clinical Practice 
Research Datalink (CPRD) primary care database linked to Hospital Episode Statistics (HES) data, and 
Office for National Statistics (ONS) mortality data.  CPRD is a computerised database of anonymised 
patient primary care records (9).  It includes records from over 11 million patients, including 4.4 
million 'active' (i.e. alive and GP registered) patients.  This is equivalent to approximately 6.9% of the 
UK population; active patients are representative of the age and sex distribution of the general 
population.  
CPRD contains demographic information, clinical diagnoses, consultations, investigations and 
prescription data. HES is a routinely collected dataset that records all episodes of care provided to all 
patients (NHS funded and privately insured) in English NHS hospitals and NHS funded patients 
treated in English independent sector hospitals (10). HES has separate datasets for admitted patient 
care (APC), covering day case or inpatient admissions to hospital; adult critical care (CC); outpatient 
activity (OP), covering outpatient appointments, radiology and procedures; and accident and 
emergency (A&E). The A&E dataset was introduced in 2007/8 and considered experimental until 
2012/13 and is not included in this analysis. 
Eligibility criteria were (see Figure 1): 1) patients eligible for CPRD, HES and ONS mortality data 
linkage; 2) ONS death date between 01/05/2012 and 30/04/2013; 3) any Read code (Appendix) 
indicating a diagnosis of HF recorded in the CPRD primary care record between 01/05/2010 and 
30/04/2013; 4) CPRD quality assessment flags indicated the patient and practice data were 
'acceptable' and 'up to standard' for use in research since at least 01/05/2010 (9).  We excluded 
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patients whose HES patient record was linked to more than one CPRD record. We also excluded 
patients who: were less than 18 years at the time of death; left the practice before death; were not 
registered with the practice for at least one year prior to death; or where the practice had not 
uploaded CPRD data since before their death. We defined the HF index date as the earliest date 
since 01/01/2004 when a primary care Read code or HES/ONS ICD10 code indicated a diagnosis of 
HF. 
 
Cost of health care 
We excluded care provided more than five years before death and the small proportion of care 
recorded as occurring after death.  The latter probably represents data entry error or planned care 
(e.g. outpatient appointments) not received.  We also excluded a small percentage of duplicate 
records. 
Costs of hospital-based care were estimated from HES data. The HES APC data record inpatient and 
day case episodes provided by one clinical team.  HES APC data can be used to identify hospital 
spells which may contain more than one episode if care is transferred from one clinical team to 
another while in the same hospital. Numerous methods have been proposed for costing hospital 
admissions, but there is no gold standard (11).  We costed admissions at the level of hospital spell, 
distinguishing between the fixed costs (e.g. initial surgery) and the variable costs of care as length of 
stay increases.  Costs were estimated based on whether the admission was elective or non-elective 
(type); more or less than two days (short stay); length of stay (days); and the healthcare resource 
group (HRG).  HRG codes provide information on the chapter (e.g. cardiac), sub-chapter (e.g. cardiac 
procedures), root (e.g. coronary artery bypass graft) and split (e.g. coronary artery bypass graft with 
complications/comorbidity score 12+) in order to group clinically and financially similar admissions. 
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Different versions of HRG codes were introduced over the study period, and the HRG root was not 
known for some admissions, particularly in earlier years.   
Each year hospitals report reference costs and episode numbers by HRG split (12). We performed 
ordinary least squares regression, weighted by number of episodes to estimate the relationship 
between 2013/14 reference costs (refcost) for each HRG-split group (i) and the following covariates: 
refcosti = β1 + β2 typei + β3 short stayi + β4 HRG rooti + β5 daysi + εi 
This provides an estimate of the fixed (β1, β2, β3, and, when available, β4) and variable (β5) costs of 
each HES admission. NHS reference costs include the cost of devices such as implantable 
cardioverter-defibrillators and cardiac resynchronisation therapy. 
English NHS hospitals also report reference costs (12) per critical care day stratified by the number of 
organs supported. For patients where the maximum number of organs supported was recorded in 
the HES dataset we used this to calculate average cost per critical care day.  For other patients we 
used the average cost per critical care day for adult patients. 
We excluded outpatient appointments that patients cancelled or did not attend.  The costs of 
outpatient appointments were estimated using national reference costs (12). Completeness of 
diagnostic coding in OP data is low; therefore, we estimated the OP attendance cost using a 
frequency weighted average of all outpatient reference costs for the specialty.  Outpatient 
procedures are recorded using OPCS procedure codes (13) which we mapped (14) to four character 
HRG root codes and national reference costs (12) were applied.   
To avoid double costing, we excluded primary care events that did not represent direct patient 
contact (e.g. administration, which is already incorporated as an overhead in national unit costs) and 
care provided outside of the primary care setting.  The remaining primary care contacts were 
grouped by mode of contact into practice-based contacts, telephone contacts and home or other 
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out of practice contacts. National unit costs (15) were used to estimate the cost of each contact 
based on the mode of contact and the staff member (GPs, allied health professionals or 
other/unknown).  The CPRD records all primary care prescriptions, including medicinal products, 
dressings and other appliances, provided to patients. There is no automated way to link therapies to 
costs.  For prescriptions, we coded the Chapter, Section and Paragraph of the drug on the British 
National Formulary (BNF) (16) and used prescription cost analysis (17) data to estimate the average 
cost of a prescription for all drugs within that paragraph of the BNF. We excluded dressings and 
other appliances from our cost analysis.  We excluded primary care investigations (e.g. physical 
examination) which are a routine part of a consultation and diagnostic procedures which coincided 
with an outpatient appointment on the assumption that these test costs were included in the HES 
outpatient dataset.  Laboratory tests (e.g. clinical biochemistry; haematology; microbiology) and 
other diagnostic services (e.g. ECG, imaging) were categorised and national reference costs were 
applied (12). 
We identified hospital care and primary care medications related to diseases of the circulatory 
system using the HRG chapter ('E') and BNF Chapter ('2') respectively.  We were unable to reliably 
distinguish primary care contacts and investigations related to the circulatory system from those 
related to other comorbidities as patients often consult GPs with multiple morbidities.  
Data analysis 
We calculated total secondary and primary care health system use (i.e. hospital days, outpatient 
contacts, primary care contacts and medications) and costs for each three-month period (quarter) 
during the last five years of life (i.e. 20 quarters).  We identified patients with left ventricular 
dysfunction based on Read codes recorded in the CPRD and ICD10 diagnosis codes recorded in HES.  
Comorbidities and the Charlson comorbidities score were calculated using published algorithms(18).  
We performed two regression analyses using a GLS random-effects model. First, we regressed health 
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system costs on HF index date and proximity to death (HF cost model).  In the second regression 
(subgroup cost model), we included additional covariates for patient age (<75, ≥75 years at cohort 
inception), gender, Charlson score, left ventricular dysfunction and underlying cause of death 
(circulatory [ICD10 chapter IX] / other) to explore the influence of these characteristics on costs. 
Results are reported as means and 95% confidence intervals (95% CI) unless otherwise specified. 
Costs are reported in 2013/14 British pounds (£1 = €1.19 = $1.58 at 2013/14 exchange rates). 
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Results: 
The cohort included 1555 patients with a mean age at the time of death of 83 (10 SD) years (Table 
1). Most (931/1555; 59.9%) patients were in hospital on the day of death. Circulatory disease was 
the underlying cause of mortality recorded for the majority of patients (895/1555; 57.6%), but 
respiratory system disease and neoplasms were also common causes of death. A small proportion 
(235/1555; 15.1%) had a HF diagnosis recorded more than five years before death.  A large 
proportion (936/1555; 60.2%) had a HF diagnosis first recorded within two years of death.  Left 
ventricular dysfunction was recorded in just over half of the patients (882/1555; 56.7%). 
All types of health care use increased with proximity to death but the pattern varied by service type 
(Figure 2). Outpatient appointments and medications increased relatively linearly, approximately 
doubling over the five-year period before death.  Patients had a mean of 0.8 (95% CI 0.7 to 0.9) 
outpatient appointments and 18.3 (95% CI 17.3 to 19.3) medications in quarter 1 compared to 1.6 
(95% CI 1.5 to 1.8) appointments and 34.4 (95% CI 32.8 to 36.0) medications prescribed in quarter 
20. In contrast the use of primary care consultations and hospital bed days increased most rapidly in 
the last 6 months of life.  During the last 3 months of life, patients spent on average 17.8 (95% CI 
16.8 to 18.8) days in hospital and had 8.8 (95% CI 8.4 to 9.1) primary care consultations. 
531 (17%) of the 3200 cardiac hospitalisations were elective admissions.  1141 (73.3%) of 1555 
patients had at least one cardiac admission (median 1, range 0 to 57). The majority of cardiac 
hospitalisations were for heart failure (35.1%) or 'non-interventional acquired cardiac conditions' 
(13.8%) (Table 2).  There were 155 admissions related to implantable devices, including 72 for 
implantation of pacemaker and 26 for implantation of cardioverter defibrillator. Non-cardiac 
admissions for urinary, respiratory and digestive system problems were common. Patients received 
a wide array of cardiovascular system medications (Table 2).  Most patients had at least one 
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prescription from the following BNF sections: diuretics (1249/1555; 80.3%); hypertension or HF 
drugs (1145/1555; 73.6%); antiplatelet drugs (975/1555; 62.7%); beta blockers (894/1555; 57.5%); 
nitrites or calcium channel blockers (894/1555; 57.5%); or lipid regulators (881/1555; 56.7%). 
Inpatient costs dominate health care costs, comprising 60-91% of cost throughout the last 5 years of 
life (Figure 3). Over the last year of life mean health care costs were £17,945 (95% CI £17,066 to 
£18,823).  Costs during the last year of life were lower in patients where HF was recorded as the 
underlying cause of death (£17,041 versus £19,171, mean difference £2,130; 95% CI £335 - £3,906) 
and in patients aged 75 or older at cohort inception (£16,248 versus £22,219, mean difference 
£5,971; 95% CI £4,045 to £7,898). In the last 3 months of life, health care costs were £8,827 (95% CI 
£8,357 to £9,296) per patient, more than 90% of which were for inpatient or critical care.   
Regression analyses demonstrate that mean quarterly healthcare costs were higher in quarters after 
HF diagnosis (£1,439; [95% CI £1,260 to £1,619]) than in quarters preceding diagnosis (Table 3; HF 
cost model).  In the subgroup cost model, adjusting for age group, gender, comorbidities, left 
ventricular dysfunction and cause of death, costs were £6,782 (95% CI £6,289 to £7,275) higher in 
the final three months of life than in an equivalent period five years before death. Older patients 
(≥75) had less expensive quarterly health care costs (-£648 [95% CI -£874 to -£423]) than younger 
patients and quarterly health care costs were higher in patients with higher Charlson comorbidity 
scores (£146 [95% CI £112 to £180] per point).  Costs were not substantially higher in patients with 
left ventricular dysfunction recorded (£230 [95% CI -£90 to £550]) and there was no strong evidence 
that costs differed by gender or in patients with a circulatory underlying cause of death. 
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Discussion: 
Key findings 
Healthcare use among people who die with or of HF increases sharply at the end of life. Younger 
patients receive the most costly care. Hospitalisation costs are the predominant health system costs, 
particularly during the last three months of life when they account for more than 90% of costs.  
Many patients with HF spend protracted periods of time receiving care in hospital at the end of life 
and the majority (60%) die in hospital. 
Comparison with other studies 
Information on the economic impact of HF at the end of life is needed to judge whether the upfront 
costs of more intensive therapy (19, 20) might be justified by long-term savings due to reduced 
hospitalisations.  However, high quality evidence on the healthcare costs of HF in the UK is scarce. 
Stewart et al (21) used an aggregate 'top down' approach to estimate that the cost of primary, 
secondary and nursing home care for the UK population of patients with HF, which was £1.47 billion 
(3.83% of NHS expenditure) in 1995; hospitalisations accounted for 69% of this expenditure.  We 
took a different 'bottom up' approach by identifying a cohort of patients with HF and used routinely 
collected data to measure their healthcare use and costs.  Our approach has the advantage of 
providing greater detail on the types of healthcare used and the variation in healthcare use between 
patients and throughout the course of HF.   
Our approach is similar to Kaul et al (22) who studied 47,970 patients with HF who died in Alberta 
between 2000 and 2006.  They estimated that the mean cost per patient during the last 6 months of 
life was $CAN 27,203 (approximately £6,600 per quarter at 2015 exchange rates) in 2006, which is in 
line with our result at the end of life (Figure 3). Farré et al (23), using routine data on all 88,195 
individuals with HF identified in primary or secondary care in Catalonia, estimated an annual cost of 
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€6,571 (approximately £1,200 per quarter at 2015 exchange rates) which is similar to our estimate in 
the three to four years before death (Figure 3). In common with our findings, both studies reported 
higher costs in younger patients and in those with more comorbidities. Although device implantation 
was relatively uncommon in our cohort, more intensive therapy in younger patients may explain the 
association between costs and age.  Kaul et al reported that the percentage of patients dying in 
hospital decreased from 60.4% in 2000 to 54.0% in 2006, compared to our observation of 59.9% in 
2012/13.  In common with previous research (24) we observed that the majority of hospitalisations, 
even at the end of life, were for comorbid non-cardiovascular conditions, most commonly kidney 
disease and respiratory problems. The high prevalence of these comorbidities may explain why 
healthcare costs were not higher in patients whose death was primarily attributed to circulatory 
disease. 
Strengths and limitations 
Our study presents novel evidence about the costs of healthcare among a relatively large 
population-based cohort of patients with HF for use by policy makers and researchers.  We used 
three data sources (CPRD, HES and ONS) that have been extensively used and validated in previous 
research (9, 25). Since 2006/7 the Quality and Outcomes Framework (26) reimbursement scheme 
has given GPs incentives to maintain a HF register and confirm diagnoses by echocardiogram or 
specialist assessment.  Therefore, recording of HF diagnoses from 2006/7 should be comprehensive.  
None of the data sources was primarily designed for economic research.  We undertook extensive 
data cleaning to de-duplicate data and avoid double counting (e.g. multiple episodes in the same 
hospital spell). We mapped resource use to nationally representative unit costs that required a 
number of estimates and assumptions. We used a novel method to distinguish between the fixed 
and variable costs of hospital admissions, rather than using fixed HRG tariffs.  Medications were 
costed according to BNF paragraph meaning that intra-paragraph variations in drug costs were 
overlooked. Given the relatively small cost of medications this is unlikely to be a major limitation. 
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We calculated the cost of healthcare for patients with HF and estimated how much that cost 
increased post-diagnosis.  The HF codes used in the CPRD identify left ventricular dysfunction but are 
not specific enough to reliably differentiate HF with preserved or reduced ejection fraction. In the 
absence of a matched control group without HF, it was impossible to fully differentiate healthcare 
costs due to HF from costs due to other age-related comorbidities.  We focussed on the last five 
years of life, when care is most expensive. An incidence cohort would be needed to fully capture all 
healthcare use from diagnosis to death.  Using these routine datasets we cannot specify whether the 
medications prescribed followed clinical guidelines or reflected changes in laboratory test results. 
Our cost estimates are conservative and do not include direct care costs such as A&E attendances, 
nursing home, hospice and social care. Tanuseputro et al (27) estimated that long-term care and 
home care costs make up substantial proportions (15.5% and 8.3% respectively) of the total costs of 
healthcare during the last year of life.  We did not measure the indirect impact on patients, carers 
and society due to morbidity and premature mortality.  These productivity losses increase the total 
economic burden of HF by between 32.3% (28) and 66.2% (1). It has been reported that people 
diagnosed with HF use an additional 1.6 hours of informal caregiving per week compared to a 
matched control group (29).   
Implications and future research 
Our findings have clear implications for clinicians and managers on the importance of implementing 
evidence-based interventions to reduce avoidable hospital admissions.  There is strong evidence that 
a number of interventions including appropriate pharmacotherapy, exercise-based rehabilitation, 
case management via telephone and home visits and multidisciplinary interventions before hospital 
discharge can substantially reduce HF readmission rates (30-32).  However there are large gaps 
between guidelines and current practice; in the UK about one in ten patients receive cardiac 
rehabilitation and many do not receive cardiology or heart failure nurse follow up (4).  
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The high hospitalisation rate in the weeks preceding death has important implications for patient-
centred care. Recognition of a transition point from active treatment towards palliative care is 
difficult, but vital in order to minimise recurrent hospitalisations at the end of life (33). Home 
palliative care services increase the probability of dying at home for those that wish to and have the 
potential to reduce costs, although evidence on cost-effectiveness is inconclusive (34).  
Despite the high prevalence of HF, there is surprisingly little research on the economic impact on 
health systems, families and societies.  Future research, particularly on residential care, informal 
care and productivity losses due to HF is needed and would strengthen the economic case for better 
prevention, diagnosis and treatment of this condition. 
Conclusions 
Healthcare costs increase sharply at the end of life and are dominated by hospital care. There is 
potential to save the health system money by better implementation of interventions that are 
known to reduce hospitalisations for HF, particularly at the end of life.  Our data on the long-term 
costs of care should help researchers and policy makers to predict whether novel methods of 
diagnosis, monitoring and therapy will be cost-effective. 
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Tables:  
Table 1 – Characteristics of the cohort 
 
 HF cohort (N=1555) 
Female; n (%) 737 (47.4) 
Age at death; mean (SD; range) 83 (10; 24-105) 
In hospital on date of death; n (%) 931 (59.9) 
Underlying cause on death certificate; n (%) 
 Circulatory system (ICD10 chapter IX) 
 Respiratory system (ICD10 chapter X) 
 Neoplasms (ICD10 chapter II) 
 Other 
 
895 (57.6) 
273 (17.6) 
157 (10.1) 
230 (14.8) 
Years since HF diagnosis recorded; n (%) 
 ≤1 yr 
 1-≤2 yrs 
 2-≤3 yrs 
 3-≤5 yrs 
 >5 yrs 
 
617 (39.7) 
319 (20.5) 
204 (13.1) 
180 (11.6) 
235 (15.1) 
Left ventricular dysfunction*; n (%) 882 (56.7) 
Co-morbidities; n (%) 
 Renal disease 
 Chronic pulmonary disease 
 Diabetes 
 Cerebrovascular disease 
 Myocardial infarction 
 Peripheral vascular disease 
 Malignancy 
 Dementia 
 Diabetes with chronic complications 
 
823 (52.9) 
614 (39.5) 
465 (29.9) 
448 (28.2) 
419 (27.0) 
373 (24.0) 
352 (22.6) 
210 (13.5) 
172 (11.1) 
Charlson score; mean (SD; range) 5.16 (2.91; 0-18) 
Region of residence; n (%) 
 North West 
 South West 
 South Central 
 West Mid. 
 SE Coastal 
 London 
 East England 
 North East  
 Yorkshire & Humber 
 East Mid. 
 
354 (22.8) 
211 (13.6) 
205 (13.2) 
202 (13.0) 
160 (10.3) 
160 (10.3) 
154 (9.9) 
46 (3.0) 
35 (2.3) 
28 (1.8) 
 
* Read codes: G581. Left ventricular failure; G5810 Acute left ventricular failure; 585f. 
Echocardiogram shows left ventricular systolic dysfunction; 585g. Echocardiogram shows left 
ventricular diastolic dysfunction; G5yy9 Left ventricular systolic dysfunction; G5yyA Left ventricular 
diastolic dysfunction. ICD10 code I50.1 Left ventricular failure.
16 
 
 
Table 2 – Frequency of cardiac hospital admissions and medications 
Cardiac admissions - HRG label [primary diagnosis] (N=3,200) n % 
 HF or cardiogenic shock 
  [Congestive heart failure] 
  [Left ventricular failure] 
  [Heart failure unspecified] 
  [Other] 
1,124 
[779] 
[193] 
[71] 
[81] 
35.1 
 
 
 
 
 Non interventional acquired cardiac conditions* 443 13.8 
 Arrhythmia or Conduction Disorders 251 7.8 
 Actual or Suspected Myocardial Infarction 233 7.3 
 Catheter** 183 5.7 
 Implantable devices*** 155 4.8 
 Syncope or Collapse 135 4.2 
 Cardiac Valve Disorders 52 1.6 
 Other 624 19.5 
   
Non-cardiac admissions – HRG chapter (n=11,976)   
 Urinary tract and male reproductive system 4,537 37.9 
 Respiratory system 1,579 13.2 
 Digestive system 1,158 9.7 
 Haematology, chemotherapy, radiotherapy & palliative 926 7.7 
 Musculoskeletal system 876 7.3 
 Other 2,900 24.2 
   
Cardiovascular system medicinal products prescribed (N=365,554) n % 
 Diuretics 73,051 20.0 
 Hypertension and HF**** 65,665 18.0 
 Antiplatelets 49,292 13.5 
 Nitrates, calcium channel blockers and other antianginal  48,429 13.3 
 Lipid regulating drugs 47,643 13.0 
 Beta-adrenoceptor blocking drugs 37,435 10.2 
 Anticoagulants and protamine 21,650 5.9 
 Positive inotropic drugs 17,772 4.9 
 Other 4,617 1.3 
 
* HRG4 code removed after 2012/13 
** Predominantly coronary angiography/arteriography 
*** Including implantation of pacemaker (n=72); implantation of cardioverter defibrillator (n=26); 
renewal / resiting / removal of devices (n=38) and other procedures (n=20) 
**** Including Vasodilator antihypertensive drugs; Centrally acting antihypertensive drugs; 
Adrenergic neurone blocking drugs; Alpha-adrenoceptor blocking drugs; Drugs affecting the renin-
angiotensin system 
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Table 3 – Health system costs by proximity to death, HF diagnosis and other characteristics 
 
 HF cost model Subgroup cost model 
 Coefficient 95% CI Coefficient 95% CI 
       
Reference* 686 569 803 348 -38 735 
Year 2 -23 -125 80 -18 -121 84 
Year 3 216 81 351 227 93 362 
Quarter 13 468 214 722 487 233 741 
Quarter 14 201 -7 408 225 17 433 
Quarter 15 369 140 598 398 170 627 
Quarter 16 582 331 834 616 364 868 
Quarter 17 780 518 1041 822 559 1084 
Quarter 18 846 524 1168 894 571 1218 
Quarter 19 2045 1624 2466 2102 1680 2524 
Quarter 20 6702 6210 7193 6782 6289 7275 
Post HF diagnosis 1439 1260 1619 1221 947 1495 
Left ventricular 
dysfunction    
230 -90 550 
Charlson score    146 112 180 
Female    108 -63 280 
Age ≥75    -648 -874 -423 
Circulatory death    -180 -360 1 
       
R-sq 0.1378   0.1500   
Patients 1555   1555   
Observations 28923   28923   
 
* In the HF cost model the reference represents the average quarterly cost of healthcare in year 1, 
for patients who have not yet been diagnosed with HF.  All other coefficients represent additional 
quarterly costs compared to this reference.  For example the quarterly cost is £1,439 higher in 
patients who have been diagnosed with HF.  In the subgroup cost model the reference represents 
the average quarterly cost of healthcare in year 1, for male patients aged less than 75, with a 
Charlson score of zero who have not yet been diagnosed with HF. All other coefficients represent 
additional quarterly costs compared to this reference.  
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Figures:  
Figure 1 Patient selection flowchart 
 
* 32 CPRD IDs removed due to more than one CPRD ID linked to a unique HES ID; 4 CPRD IDs 
removed as death < 18 years; 254 CPRD IDs removed as patient transferred out before death or 
practice data not updated since death; 153 CPRD IDs removed as patient registered with practice 
less than 1 year before death. 
CPRD GOLD patients eligible for 
linkage to HES/ONS 
N= 7690294  
Death 01/05/12 – 30/04/13 
n= 53285 
Excluded 
n= 7637009 
Read code indicating HF 
01/05/10 – 30/04/13 
n=2037 
Excluded 
n= 51248 
Patient & GP research standard 
data 
N=1998 
Excluded 
n=39 
Unique CPRD - HES ID link; age at 
death > 18; registered for >365 
days & at death; practice data 
updated since death  
n=1555 
Excluded* 
n=443 
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Figure 2 – Use of healthcare resources in 3 month periods (quarters) leading up to death (different y-
axis scales) 
 
 
 
20 
 
 
 
 
a) Days in hospital 
b) Outpatient appointments 
c) Primary care consultations 
d) Prescribed medicinal items 
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Figure 3 – Cost of primary and secondary care in 3 month periods (quarters) leading up to death 
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